Opexa Therapeutics Inc. (NASDAQ:OPXA) was down 2.7% during mid-day trading on Wednesday . The stock traded as low as $4.03 and last traded at $4.27, with a volume of 115,040 shares changing hands. The stock had previously closed at $4.39.

Several equities research analysts recently issued reports on OPXA shares. Maxim Group reissued a “buy” rating on shares of Opexa Therapeutics in a research report on Friday, June 10th. Aegis reissued a “buy” rating and set a $9.00 price target on shares of Opexa Therapeutics in a research report on Wednesday, March 16th. Finally, Chardan Capital restated a “buy” rating and set a $6.00 price objective on shares of Opexa Therapeutics in a research note on Sunday, July 3rd.

The company’s market capitalization is $29.60 million. The company has a 50-day moving average price of $3.69 and a 200 day moving average price of $2.60.

Opexa Therapeutics (NASDAQ:OPXA) last released its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. During the same period last year, the firm earned ($0.96) earnings per share. Analysts anticipate that Opexa Therapeutics Inc. will post ($0.99) earnings per share for the current year.

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company’s T-cell technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.